ClinicalTrials.gg
RecruitingNCT04432220Updated Feb 6, 2023

AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)

A Phase 4 interventional study of Anticoagulation group(Apixaban group) in Atrial Fibrillation Patients With Moderate or High Stroke Risk Who Had Undergone Catheter Ablation of Atrial Fibrillation, sponsored by Yonsei University. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-02-06.

Sponsored by Yonsei University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2020; still recruiting 6 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
840
Allocation
Randomized
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies testing apixaban in Atrial Fibrillation — 10 open to participants now, 11 under way, 4 of them phase 3. apixaban · Atrial Fibrillation.

Planned enrollment
13th of 30
840 · median 498
Started
2020
with 1 other
Phase 4
13 of 30
5 open now
Primary completion
2026-07
later than 0 of 10 live
Registered
23rd of 30
by date

Among the 30 studies testing apixaban in Atrial Fibrillation, this one is the 13th largest by planned enrollment, is one of 2 that started in 2020, is one of 13 in phase 4, reaches primary completion later than 0 of the 10 other live ones, and was the 23rd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

10 of the 30 studies testing apixaban in Atrial Fibrillation are open now, in 10 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing apixaban in Atrial Fibrillation, or all of them as a file.
02

Study summary

There has no evidence for the anticoagulation in patients who had undergone catheter ablation of atrial fibrillation, and has maintained sinus rhythm for more than 1 year. However, anticoagulation can increase the risk of bleeding, the study evaluating the role of oral anticoagulation is needed in this patients. This study will compare the efficacy and safety of non-vitamin K anticoagulants (apixaban) and no oral anticoagulation in patient with sinus rhythm one year after catheter ablation of AF.

Read the detailed description

This study is a prospective randomized study which was performed in multicenter (General Hospital) in Korea. Inclusion criteria is atrial fibrillation patients with moderate or high stroke risk (CHA2DS2-VASc>=1 male, and >=2 female) who had undergone catheter ablation of atrial fibrillation, and has maintained sinus rhythm for more than 1 year. Anticoagulation (Apixaban group) will take apixaban (5 mg bid or 2.5 mg bid according to dose guideline) for 2 years, and nonanticoagulation group will not take any oral anticoagulants for the same period. If the patients have the recurrence of AF, they will take anticoagulation according to standard treatment, and will be censored. We will analyze and compare the efficacy and safety of non-vitamin K anticoagulants (apixaban) and no oral anticoagulation in these patients.

03

Conditions studied

  • Atrial Fibrillation Patients With Moderate or High Stroke Risk Who Had Undergone Catheter Ablation of Atrial Fibrillation

Keywords

  • catheter ablation
  • anticoagulation
  • efficacy
  • safety
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. no recurrence of atrial fibrillation one year after catheter ablation of atrial fibrillation
  2. CHA2DS2-VASc score >=1 (male) or >=2 (female)
  3. age: 19 to 80 years
  4. non-valvular atrial fibrillation
  5. those who consent the study.
  6. those who can be followed after enrollment

Exclusion criteria

Exclusion Criteria:

  1. Severe liver or kidney dysfunction
  2. Thyroid dysfunction
  3. Pregnant or breastfeeding women
  4. Malignant tumors that have not been completely cured
  5. Severe structural heart disease
  6. Predicted survival is less than 12 months
  7. Patients who do not understand the content of the study or disagree with it
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
840 participants (estimated)

Study arms

  • Experimental
    Anticoagulation group(Apixaban group)

    Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years

    Drug: Anticoagulation group(Apixaban group)

  • No intervention
    Nonanticoagulation group

    Standard treatment except anticoagulant for 2 years

Interventions

  • DrugApixabanStudies of ApixabanApixaban pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years

06

What researchers measure

Primary outcomes

  1. Composite outcome

    composite outcome including stroke/systemic embolism and major bleeding

    Time frame: Baseline

  2. Composite outcome

    composite outcome including stroke/systemic embolism and major bleeding

    Time frame: 1 month

  3. Composite outcome

    composite outcome including stroke/systemic embolism and major bleeding

    Time frame: 6 months

  4. Composite outcome

    composite outcome including stroke/systemic embolism and major bleeding

    Time frame: 12 months

  5. Composite outcome

    composite outcome including stroke/systemic embolism and major bleeding

    Time frame: 18 months

  6. Composite outcome

    composite outcome including stroke/systemic embolism and major bleeding

    Time frame: 24 months

Secondary outcomes

  1. Stroke

    Ischemic stroke specifically refers to central nervous system infarction (brain, spinal cord, or retinal cell death attributable to ischemia) accompanied by overt symptoms, while silent infarction by definition causes no known symptoms. Stroke also broadly includes intracerebral hemorrhage and subarachnoid hemorrhage.

    Time frame: Baseline

  2. Stroke

    Ischemic stroke specifically refers to central nervous system infarction (brain, spinal cord, or retinal cell death attributable to ischemia) accompanied by overt symptoms, while silent infarction by definition causes no known symptoms. Stroke also broadly includes intracerebral hemorrhage and subarachnoid hemorrhage.

    Time frame: 1 month

  3. Stroke

    Ischemic stroke specifically refers to central nervous system infarction (brain, spinal cord, or retinal cell death attributable to ischemia) accompanied by overt symptoms, while silent infarction by definition causes no known symptoms. Stroke also broadly includes intracerebral hemorrhage and subarachnoid hemorrhage.

    Time frame: 6 months

  4. Stroke

    Ischemic stroke specifically refers to central nervous system infarction (brain, spinal cord, or retinal cell death attributable to ischemia) accompanied by overt symptoms, while silent infarction by definition causes no known symptoms. Stroke also broadly includes intracerebral hemorrhage and subarachnoid hemorrhage.

    Time frame: 12 months

  5. Stroke

    Ischemic stroke specifically refers to central nervous system infarction (brain, spinal cord, or retinal cell death attributable to ischemia) accompanied by overt symptoms, while silent infarction by definition causes no known symptoms. Stroke also broadly includes intracerebral hemorrhage and subarachnoid hemorrhage.

    Time frame: 18 months

  6. Stroke

    Ischemic stroke specifically refers to central nervous system infarction (brain, spinal cord, or retinal cell death attributable to ischemia) accompanied by overt symptoms, while silent infarction by definition causes no known symptoms. Stroke also broadly includes intracerebral hemorrhage and subarachnoid hemorrhage.

    Time frame: 24 months

  7. Major bleeding

    The International Society on Thrombosis and Haemostasis (ISTH)/Scientific and Standardization Committee (SSC) definitions and bleeding assessment tool are useful for standardizing the reporting of bleeding symptoms. 1. Fatal bleeding. and/or 2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome. and/or 3. Bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells.

    Time frame: Baseline

  8. Major bleeding

    The International Society on Thrombosis and Haemostasis (ISTH)/Scientific and Standardization Committee (SSC) definitions and bleeding assessment tool are useful for standardizing the reporting of bleeding symptoms. 1. Fatal bleeding. and/or 2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome. and/or 3. Bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells.

    Time frame: 1 month

  9. Major bleeding

    The International Society on Thrombosis and Haemostasis (ISTH)/Scientific and Standardization Committee (SSC) definitions and bleeding assessment tool are useful for standardizing the reporting of bleeding symptoms. 1. Fatal bleeding. and/or 2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome. and/or 3. Bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells.

    Time frame: 6 months

  10. Major bleeding

    The International Society on Thrombosis and Haemostasis (ISTH)/Scientific and Standardization Committee (SSC) definitions and bleeding assessment tool are useful for standardizing the reporting of bleeding symptoms. 1. Fatal bleeding. and/or 2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome. and/or 3. Bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells.

    Time frame: 12 months

  11. Major bleeding

    The International Society on Thrombosis and Haemostasis (ISTH)/Scientific and Standardization Committee (SSC) definitions and bleeding assessment tool are useful for standardizing the reporting of bleeding symptoms. 1. Fatal bleeding. and/or 2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome. and/or 3. Bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells.

    Time frame: 18 months

  12. Major bleeding

    The International Society on Thrombosis and Haemostasis (ISTH)/Scientific and Standardization Committee (SSC) definitions and bleeding assessment tool are useful for standardizing the reporting of bleeding symptoms. 1. Fatal bleeding. and/or 2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome. and/or 3. Bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells.

    Time frame: 24 months

  13. Clinically Relivant Non-Major Bleeding (CRNMB)

    - Clinically Relivant Non-Major Bleeding (CRNMB) : 1. Any sign or symptom of hemorrhage (e.g., more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for the ISTH definition of major bleeding but does meet at least one of the following criteria: 2. ISTH major bleeding in non-surgical patients is defined as having a symptomatic presentation and 1:

    Time frame: Baseline, 1month, 6 month, 12 month, 18 month, 24 month

  14. Death

    Death: the permanent stopping of all the vital bodily activities

    Time frame: Baseline, 1month, 6 month, 12 month, 18 month, 24 month

  15. Transient ischemic attack (TIA)

    TIA is brief episodes of neurological dysfunction resulting from focal cerebral ischemia not associated with permanent cerebral infarction.

    Time frame: Baseline, 1month, 6 month, 12 month, 18 month, 24 month

  16. Hospital admission

    Hospital admission means admission of a covered person to a hospital as an inpatient for medically necessary and appropriate care and treatment of an Illness or Injury.

    Time frame: Baseline, 1month, 6 month, 12 month, 18 month, 24 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Jul 2026, 72 months after the start.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 72 months is above that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2020
First posted
Jun 16, 2020
StartActual
Jul 28, 2020
Primary completionEst.
Jul 2026
CompletionEst.
Oct 2028
Last update
Feb 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04432220
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Jun 16, 2020
Start date
Jul 28, 2020
Primary completion
Jul 2026 (estimated)
Completion
Oct 2028 (estimated)
Last update
Feb 6, 2023

Study contacts

Boyoung Joung, Ph.D
Contact
cby6908@yuhs.ac
82-2-2228-8447

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion